NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $3.43 +0.10 (+3.00%) As of 06/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Puma Biotechnology Stock (NASDAQ:PBYI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Puma Biotechnology alerts:Sign Up Key Stats Today's Range$3.33▼$3.4350-Day Range$2.90▼$3.7252-Week Range$2.23▼$4.13Volume374,468 shsAverage Volume415,496 shsMarket Capitalization$170.23 millionP/E Ratio4.45Dividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More… Puma Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScorePBYI MarketRank™: Puma Biotechnology scored higher than 85% of companies evaluated by MarketBeat, and ranked 158th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has received no research coverage in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth22.58% Earnings GrowthEarnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 4.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 4.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.44.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.19% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Puma Biotechnology has recently decreased by 3.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.19% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Puma Biotechnology has recently decreased by 3.60%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.71 News SentimentPuma Biotechnology has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.Search Interest2 people have searched for PBYI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $311,563.00 in company stock.Percentage Held by Insiders23.30% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address PBYI Stock News HeadlinesInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - NasdaqJune 26, 2025 | nasdaq.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 1 at 2:00 AM | Crypto 101 Media (Ad)Puma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25, 2025 | seekingalpha.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comPuma Biotech CCO Jeff Ludwig departs, no replacement namedMay 10, 2025 | uk.investing.comSee More Headlines PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $3.05 at the beginning of the year. Since then, PBYI stock has increased by 12.5% and is now trading at $3.43. View the best growth stocks for 2025 here. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) released its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.29. The biopharmaceutical company earned $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a net margin of 16.37% and a trailing twelve-month return on equity of 49.35%. Read the conference call transcript. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA). Company Calendar Last Earnings2/27/2025Today7/01/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+104.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.77 Trailing P/E Ratio4.45 Forward P/E Ratio11.06 P/E GrowthN/ANet Income$30.28 million Net Margins16.37% Pretax Margin13.73% Return on Equity49.35% Return on Assets18.25% Debt Debt-to-Equity Ratio0.11 Current Ratio1.53 Quick Ratio1.43 Sales & Book Value Annual Sales$230.50 million Price / Sales0.74 Cash Flow$0.88 per share Price / Cash Flow3.91 Book Value$1.88 per share Price / Book1.82Miscellaneous Outstanding Shares49,630,000Free Float38,067,000Market Cap$170.23 million OptionableOptionable Beta1.29 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:PBYI) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.